ResultsIQ

ResultsIQ › Latest results › Gaudium IVF and Women Health Limited

Gaudium IVF and Women Health Limited Q1 FY27 earnings call summary

NSE: GAUDIUMIVF · BSE: 544709

Earnings call of 14 Aug 2026, summarised by AI from the filing.

Gaudium IVF Q1 FY27 revenue rose 9.1% to ₹19.4 cr while EBITDA margin fell to 12.5%, and management guides 30% FY27 revenue growth.

Key takeaways

  1. FY27 guidance Management guides 30% year-on-year revenue growth for FY27 and adjusted EBITDA margins similar to FY26 levels.
  2. Growth driver AI embryology tools SiD and ERICA, integrated from 1 April, show approximately 8% improvement in first attempt outcomes.
  3. Main risk ART Act implementation is at various stages across states and may take another year to execute properly.

Original filing on BSE

Gaudium IVF and Women Health Limited Q1 FY27 results

As filed: Revenue ₹19.4 cr, EBITDA ₹2.4 cr, PAT ₹1.8 cr, EBITDA margin 12.5%.

Not scored. Too small to score: quarter revenue ₹19.4 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹30.4 cr, EBITDA ₹12.2 cr, PAT ₹8.4 cr, EBITDA margin 40.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹30.4 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −7.0% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹24.5 cr, EBITDA ₹6.6 cr, PAT ₹3.6 cr, EBITDA margin 26.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹24.5 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +2.2% in 30 days (Nifty 500: +4.3%).

Past price moves after results do not indicate future moves. Not a recommendation.

Gaudium IVF and Women Health Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.